Overview Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery Status: Not yet recruiting Trial end date: 2024-03-01 Target enrollment: Participant gender: Summary Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery Phase: Phase 4 Details Lead Sponsor: Nicole Fram M.D.Treatments: BromfenacDexamethasoneMethylprednisoloneMethylprednisolone AcetateMethylprednisolone HemisuccinateMoxifloxacinPrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphate